407 related articles for article (PubMed ID: 28815334)
1. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.
Rossi S; Toschi L; Castello A; Grizzi F; Mansi L; Lopci E
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2310-2325. PubMed ID: 28815334
[TBL] [Abstract][Full Text] [Related]
2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
3. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
[TBL] [Abstract][Full Text] [Related]
4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
6. Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis.
Mulkey F; Theoret MR; Keegan P; Pazdur R; Sridhara R
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32107275
[TBL] [Abstract][Full Text] [Related]
7. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
9. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Davis AA; Patel VG
J Immunother Cancer; 2019 Oct; 7(1):278. PubMed ID: 31655605
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
11. [The use of immune checkpoint inhibitors in routine oncology].
Schardt J
Z Rheumatol; 2020 Oct; 79(8):809-817. PubMed ID: 32936368
[TBL] [Abstract][Full Text] [Related]
12. The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art.
Castello A; Lopci E
Curr Radiopharm; 2020; 13(1):24-31. PubMed ID: 31749440
[TBL] [Abstract][Full Text] [Related]
13. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).
Sun R; Champiat S; Dercle L; Aspeslagh S; Castanon E; Limkin EJ; Baldini C; Postel-Vinay S; Hollebecque A; Massard C; Ammari S; Deutsch E; Soria JC; Marabelle A; Ferté C
Eur J Cancer; 2017 Oct; 84():202-211. PubMed ID: 28826073
[TBL] [Abstract][Full Text] [Related]
14. Tumor response assessment on imaging following immunotherapy.
Berz AM; Dromain C; Vietti-Violi N; Boughdad S; Duran R
Front Oncol; 2022; 12():982983. PubMed ID: 36387133
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
16. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
17. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Meng X; Huang Z; Teng F; Xing L; Yu J
Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
19. Current studies of immunotherapy in head and neck cancer.
Dogan V; Rieckmann T; Münscher A; Busch CJ
Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
[TBL] [Abstract][Full Text] [Related]
20. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
